New guidelines from the NCCN for polycythemia vera.
Authors: Mesa RA PMID: 29200417 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 5, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunotherapy in ovarian cancer: where are we now, and where are we going?
Authors: Jazaeri AA PMID: 29200418 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 5, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A mind map for managing minimal residual disease in acute myeloid leukemia.
Authors: Benton CB, Ravandi F Abstract Advances in detecting traces of leukemia that were previously unidentifiable have increasingly led to the incorporation of information about residual disease into clinical decision making for patients with leukemia in both the postinduction and consolidation settings. This review discusses current concepts related to minimal residual disease (MRD), which is defined as submicroscopic disease detected during morphologic complete remission. The focus is on acute myeloid leukemia (AML). Basic methods for detecting MRD include flow cytometry, reverse transcription-polymerase chain ...
Source: Clinical Advances in Hematology and Oncology - December 5, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The effect of novel therapies in high-molecular-risk multiple myeloma.
Authors: Lancman G, Tremblay D, Barley K, Barlogie B, Cho HJ, Jagannath S, Madduri D, Moshier E, Parekh S, Chari A Abstract Multiple myeloma is a heterogeneous disease with a prognosis that varies with patient factors, disease burden, tumor biology, and treatments. Certain molecular abnormalities confer a worse prognosis and thus are considered high-risk. These include t(4;14), del(17p), t(14;16), t(14;20), hypodiploidy, and gain(1q)/del(1p). In our previous review in 2013, we discussed the effect of available therapies on prognosis in these high-risk patients. Since then, seven phase 3 clinical trials in relapsed ...
Source: Clinical Advances in Hematology and Oncology - December 5, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter from the Editor: How to treat Hodgkin lymphoma.
Authors: Kahl BS PMID: 29040249 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

What is the optimal duration of adjuvant therapy in colon cancer?
Authors: Shields AF PMID: 29040251 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.
Authors: Flaherty K PMID: 29040252 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Direct-to-consumer advertising of cancer treatments.
Authors: Schnipper LE PMID: 29040253 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

When to initiate treatment in smoldering multiple myeloma.
Authors: Mateos MV PMID: 29040254 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How I treat stage IV non-small cell lung cancer in the absence of any actionable oncogenic driver.
Authors: Socinski MA PMID: 29040255 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of genomics in patients with advanced prostate cancer.
Authors: Hussain MH PMID: 29040256 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current challenges in the management of essential thrombocythemia.
Authors: Kleman A, Singavi AK, Michaelis LC Abstract Essential thrombocythemia (ET), an uncommon blood cancer, is one of the classic myeloproliferative neoplasms, a category that also includes polycythemia vera and primary myelofibrosis. All 3 diseases are clonal hematopoietic stem cell disorders. Since 2005, when scientists discovered a molecular aberration driving clonal hematopoiesis in polycythemia vera, our understanding of the genomic underpinnings of these conditions has increased rapidly. Over the last decades, primary prevention of thrombotic and hemorrhagic complications has improved the lives of patients...
Source: Clinical Advances in Hematology and Oncology - October 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer.
Authors: Schweizer MT, Antonarakis ES Abstract Recent work directed toward understanding the molecular features of advanced prostate cancers has revealed a relatively high incidence of both germline and somatic alterations in genes involved in DNA damage repair (DDR). Many of these alterations likely play a critical role in the pathogenesis of more aggressive prostate cancers-leading to genomic instability and an increased probability of the development of lethal disease. However, because the ability to repair DNA damage with a high degree of fidelity is critical to an individual cell's survival, tumor cells harbor...
Source: Clinical Advances in Hematology and Oncology - October 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The treatment path in hepatocellular carcinoma.
Authors: El-Serag HB, Zhu AX, Johnson MS Abstract The treatment approach for hepatocellular carcinoma (HCC) depends on the stage and extent of disease, the severity of the underlying liver disease, and the overall performance status of the patient. Treatment consists of 4 main strategies: surgery (eg, resection and liver transplant), locoregional procedures (eg, ablation and transarterial embolization), systemic therapies, and best supportive care. For patients with early-stage tumors, surgical treatment or ablation can be curative. Patients with intermediate-stage disease can be candidates for embolization, admini...
Source: Clinical Advances in Hematology and Oncology - October 18, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in the management of hepatocellular carcinoma.
Authors: El-Serag HB PMID: 29036036 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 18, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent developments in systemic therapy for hepatocellular carcinoma.
Authors: Zhu AX PMID: 29036037 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 18, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The evolving role of radioembolization in hepatocellular carcinoma.
Authors: Johnson MS PMID: 29036038 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 18, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The treatment path in hepatocellular carcinoma: Further observations.
Authors: Johnson MS PMID: 29036039 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 18, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Frontline management of chronic lymphocytic leukemia.
Authors: Furman RR PMID: 29036040 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 18, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting and the 14th International Conference on Malignant Lymphoma.
Authors: PMID: 29036041 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 18, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Lymphoma From the 2017 ASCO Meeting and the 14th ICML: Commentary.
Authors: Moskowitz CH PMID: 29036042 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 18, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Book club: the Panama Canal.
Authors: Kahl BS PMID: 28949935 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Optimal treatment for platinum-sensitive recurrent ovarian cancer.
Authors: Monk BJ PMID: 28949936 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in the management of primary central nervous system lymphoma.
Authors: Dunleavy K PMID: 28949937 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The value in cancer care consortium: addressing financial toxicity.
Authors: Lichter AS PMID: 28949938 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in kidney cancer from the 2017 American Society of Clinical Oncology Annual Meeting.
Authors: PMID: 28949939 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
Authors: George DJ PMID: 28949940 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Authors: Maffioli M, Mora B, Passamonti F Abstract Polycythemia vera (PV) is a Philadelphia chromosome-negative chronic myeloproliferative neoplasm that is associated with a Janus kinase 2 (JAK2) mutation in most cases. The most recent update to the World Health Organization diagnostic criteria for PV was published in 2016. These were the modifications with the greatest effect: (1) lowering the hemoglobin threshold, allowing a diagnosis of PV at 16.5 g/dL in males and at 16.0 g/dL in females and (2) introducing a hematocrit cutoff (49% in males and 48% in females). Patients with PV who are older than 60 y...
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Testicular seminoma: oncologic rationale and role of surgery in treatment.
Authors: Yerram NK, Arora HC, Khanna A, Ericson K, Sun AY, Babbar P, Nandanan N, Stephenson AJ Abstract Seminomas account for approximately 50% of all cases of testicular cancer. Testicular cancer is a highly curable disease that can be broadly classified as either seminomatous or nonseminomatous; the management and treatment of the 2 forms vary widely. Although surgery plays a large role in the management of nonseminoma, its role in the management of seminoma is much more limited. Most clinicians in the United States choose orchiectomy followed by surveillance for patients with stage I seminomatous disease, and ch...
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Take back the research.
Authors: Kahl BS PMID: 28949943 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of D-dimer testing in clinical hematology and oncology.
Authors: Greenberg CS PMID: 28949944 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent insights into the use of combination immunotherapy in solid tumors.
Authors: Luke JJ PMID: 28949945 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Does plasma-based molecular testing have a role in the routine care of lung cancer?
Authors: Wakelee H PMID: 28949946 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of autologous stem cell transplant in patients with multiple myeloma.
Authors: Mikhael JR PMID: 28949947 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in breast cancer from the 2017 American Society of Clinical Oncology Annual Meeting.
Authors: Rugo HS PMID: 28949948 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The next frontier in non-small cell lung cancer: synergizing radiation therapy and immune checkpoint blockade.
This article reviews the potential use of immunotherapeutic strategies combined with radiation therapy in patients with NSCLC, focusing on ICB. It describes the mechanism of action of immune checkpoint inhibitors, summarizes published studies that demonstrate the benefit of immune checkpoint inhibitors in advanced NSCLC, and provides the preclinical and clinical rationale supporting the potential immunologic synergy of radiation and ICB. PMID: 28949949 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New treatments for stage I testicular cancer.
Authors: Nappi L, Nichols CR, Kollmannsberger CK Abstract Clinical stage I represents the most frequent presentation of both seminoma and nonseminoma testicular cancer. Despite a survival rate of close to 100%, the management of patients with this disease stage is controversial. The recurrence rate is 10% to 20% for patients with stage I seminoma and 15% to 50% for those with stage I nonseminoma. A highly sensitive and specific biomarker of relapse that is applicable to both seminoma and nonseminoma, and able to drive a definitive risk-adapted management of the patients, still is not available. Lymphovascular invas...
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.
Authors: Percival ME, Estey E Abstract Acute myeloid leukemia (AML) is rare and difficult to treat. Although remission is achieved in most patients with newly diagnosed disease, relapse occurs in most cases. For more than 40 years, the standard up-front induction treatment has been a combination of continuous-infusion cytarabine and an anthracycline. Risk stratification by molecular and cytogenetic characteristics and measurable residual disease (MRD) status informs decisions regarding referral to consolidative allogeneic hematopoietic cell transplant. In 2017, for the first time in years, 4 drugs are under conside...
Source: Clinical Advances in Hematology and Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights From the XVII International Workshop on Chronic Lymphocytic Leukemia.
Authors: PMID: 28837122 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 26, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights From the XVII International Workshop on Chronic Lymphocytic Leukemia: Commentary.
Authors: O'Brien SM PMID: 28837123 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 26, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Aggressive Non-Hodgkin Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting.
Authors: PMID: 28837124 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 26, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Aggressive Non-Hodgkin Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary.
Authors: Locke FL PMID: 28837125 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 26, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting.
Authors: PMID: 28837126 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 26, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary.
Authors: Matulonis UA PMID: 28837127 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 26, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: in memory of Robert L. Comis, MD.
Authors: Kahl BS PMID: 28749901 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Programmed death ligand 1 testing: is there one best test?
Authors: Hirsch FR PMID: 28749902 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Drug development for rare cancers in children.
Authors: Gore L PMID: 28749903 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Use of genetic markers in multiple myeloma.
Authors: Fonseca R PMID: 28749904 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The BALAD-2 and GALAD biomarker models for hepatocellular carcinoma.
Authors: Johnson PJ PMID: 28749905 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Locoregional therapy for liver metastases in colorectal cancer.
Authors: Kennedy AS PMID: 28749906 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 28, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research